Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer

Oncotarget

Volumn 5, Issue 18, 2014, Pages 8492-8502

  Ress, Anna Lena ^a   Stiegelbauer, Verena ^a   Schwarzenbacher, Daniela ^a   Deutsch, Alexander ^a   Perakis, Samantha ^a   Ling, Hui ^b   Ivan, Cristina ^b   Calin, George Adrian ^b   Rinner, Beate ^a   Gerger, Armin ^a   Pichler, Martin ^a,b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cellular growth; Colorectal cancer; Prognosis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; FLUOROURACIL; PROTEIN P53; SHORT HAIRPIN RNA; SPINOPHILIN; TRANSCRIPTION FACTOR E2F1; TRICHOSTATIN A; ACTIN BINDING PROTEIN; ANTINEOPLASTIC ANTIMETABOLITE; CD133 ANTIGEN; E2F1 PROTEIN, HUMAN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; NERVE PROTEIN; NEURABIN; PEPTIDE; TP53 PROTEIN, HUMAN;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CACO 2 CELL LINE; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; COHORT ANALYSIS; COLON ADENOCARCINOMA; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; HCT116 CELL LINE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; PHENOTYPE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR GROWTH; ADENOCARCINOMA; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA METHYLATION; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC TRANSFECTION; GENETICS; HT 29 CELL LINE; METABOLISM; MORTALITY; MULTICELLULAR SPHEROID; MUTATION; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTOR;

ADENOCARCINOMA; ANTIGENS, CD; ANTIMETABOLITES, ANTINEOPLASTIC; CACO-2 CELLS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; E2F1 TRANSCRIPTION FACTOR; EPIGENESIS, GENETIC; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HCT116 CELLS; HT29 CELLS; HUMANS; MICROFILAMENT PROTEINS; MUTATION; NEOPLASTIC STEM CELLS; NERVE TISSUE PROTEINS; PEPTIDES; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TIME FACTORS; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84907993260     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2329     Document Type: Article

References (24)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64(1):9-29.
2. Prenen H, Vecchione L and Van Cutsem E. Role of targeted agents in metastatic colorectal cancer. Targeted oncology. 2013; 8(2):83-96.
3. Mohan S, Heitzer E, Ulz P, Lafer I, Lax S, Auer M, Pichler M, Gerger A, Eisner F, Hoefler G, Bauernhofer T, Geigl JB and Speicher MR. Changes in colorectal carcinoma genomes under anti-EGFR therapy identified by whole-genome plasma DNA sequencing. PLoS genetics. 2014; 10(3):e1004271.
4. Pichler M, Ress AL, Winter E, Stiegelbauer V, Karbiener M, Schwarzenbacher D, Scheideler M, Ivan C, Jahn SW, Kiesslich T, Gerger A, Bauernhofer T, Calin GA and Hoefler G. MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients. British journal of cancer. 2014; 110(6):1614-1621.
5. Szkandera J, Pichler M, Absenger G, Stotz M, Weissmueller M, Samonigg H, Asslaber M, Lax S, Leitner G, Winder T, Renner W and Gerger A. A functional germline variant in GLI1 implicates hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20(6):1687-1697.
6. Carnero A. Spinophilin: A New Tumor Suppressor at 17q21. Current Molecular Medicine. 2012; 12(5):528-535.
7. Vilar E and Tabernero J. Molecular dissection of microsatellite instable colorectal cancer. Cancer discovery. 2013; 3(5):502-511.
8. Aigelsreiter AM, Aigelsreiter A, Wehrschuetz M, Ress AL, Koller K, Salzwimmer M, Gerger A, Schauer S, Bauernhofer T and Pichler M. Loss of the putative tumor suppressor protein spinophilin is associated with poor prognosis in head and neck cancer. Human pathology. 2014; 45(4):683-690.
9. Ferrer I, Blanco-Aparicio C, Peregrina S, Cañamero M, Fominaya J, Cecilia Y, lleonart M, Hernandez-Losa J, Ramon y Cajal S and Carnero A. Spinophilin acts as a tumor suppressor by regulating Rb phosphorylation. Cell Cycle. 2011; 10(16):2751-2762.
10. Aigelsreiter A, Ress AL, Bettermann K, Schauer S, Koller K, Eisner F, Kiesslich T, Stojakovic T, Samonigg H, Kornprat P, Lackner C, Haybaeck J and Pichler M. Low expression of the putative tumour suppressor spinophilin is associated with higher proliferative activity and poor prognosis in patients with hepatocellular carcinoma. British journal of cancer. 2013; 108(9):1830-1837.
11. Estevez-Garcia P, Lopez-Calderero I, Molina-Pinelo S, Munoz-Galvan S, Salinas A, Gomez-Izquierdo L, Lucena-Cacace A, Felipe-Abrio B, Paz-Ares L, Garcia-Carbonero R and Carnero A. Spinophilin loss correlates with poor patient prognosis in advanced stages of colon carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(14):3925-3935.
12. Altman DG and Royston P. What do we mean by validating a prognostic model? Statistics in medicine. 2000; 19(4):453-473.
13. Prensner JR, Sahu A, Iyer MK, Malik R, Chandler B, Asangani IA, Poliakov A, Vergara IA, Alshalalfa M, Jenkins RB, Davicioni E, Feng FY and Chinnaiyan AM. The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget. 2014; 5(6):1434-1438.
14. Wilson PM, Danenberg PV, Johnston PG, Lenz HJ and Ladner RD. Standing the test of time: targeting thymidylate biosynthesis in cancer therapy. Nature reviews Clinical oncology. 2014; 11(5):282-298.
15. Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G and Lenz HJ. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(17):5783-5792.
16. Heitzer E, Auer M, Gasch C, Pichler M, Ulz P, Hoffmann EM, Lax S, Waldispuehl-Geigl J, Mauermann O, Lackner C, Hofler G, Eisner F, Sill H, Samonigg H, Pantel K, Riethdorf S, et al. Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer research. 2013; 73(10):2965-2975.
17. Heitzer E, Auer M, Hoffmann EM, Pichler M, Gasch C, Ulz P, Lax S, Waldispuehl-Geigl J, Mauermann O, Mohan S, Pristauz G, Lackner C, Hofler G, Eisner F, Petru E, Sill H, et al. Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer. International journal of cancer Journal international du cancer. 2013; 133(2):346-356.
18. Ling H, Spizzo R, Atlasi Y, Nicoloso M, Shimizu M, Redis RS, Nishida N, Gafa R, Song J, Guo Z, Ivan C, Barbarotto E, De Vries I, Zhang X, Ferracin M, Churchman M, et al. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome research. 2013; 23(9):1446-1461.
19. Stintzing S and Lenz HJ. Molecular Pathways: Turning Proteasomal Protein Degradation into a Unique Treatment Approach. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014 ;15;20(12):3064-3070.
20. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C and De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007; 445(7123):111-115.
21. Zhai JM, Yin XY, Lai YR, Hou X, Cai JP, Hao XY, Liang LJ and Zhang LJ. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1. Cancer chemotherapy and pharmacology. 2013; 71(5):1255-1264.
22. network Tcga. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407):330-337.
23. Mossman D, Kim KT and Scott RJ. Demethylation by 5-aza-2'-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists. BMC cancer. 2010; 10:366.
24. Wei B, Han XY, Qi CL, Zhang S, Zheng ZH, Huang Y, Chen TF, Wei HB. Coaction of spheroid-derived stem-like cells and endothelial progenitor cells promotes development of colon cancer. PLoS One. 2012; 7(6): e39069.